Concurrent alterations of O‐GlcNAcylation and phosphorylation of tau in mouse brains during fasting

No abstract is available for this paper.

• Publication year

  2006

• Venue

  European Journal of Neuroscience

• Publication date

  2006-04-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1111/j.1460-9568.2006.04735.xPMID 16630055
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Post-translational modifications of tau protein in Alzheimer’s disease

  2005cited by this paper
• Physiological and Pathological Changes in Glucose Regulate Brain Akt and Glycogen Synthase Kinase-3*

  2005cited by this paper
• Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation

  2005cited by this paper
• Insulin signaling, diabetes mellitus and risk of Alzheimer disease

  2005cited by this paper
• Metabolic/signal transduction hypothesis of Alzheimer’s disease and other tauopathies

  2005cited by this paper
• O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease.

  2004cited by this paper
• A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads

  2004cited by this paper
• Alterations in Glucose Metabolism Induce Hypothermia Leading to Tau Hyperphosphorylation through Differential Inhibition of Kinase and Phosphatase Activities: Implications for Alzheimer's Disease

  2004cited by this paper
• Injection of okadaic acid into the meynert nucleus basalis of rat brain induces decreased acetylcholine level and spatial memory deficit.

  2004cited by this paper
• ApoE genotype accounts for the vast majority of AD risk and AD pathology.

  2004cited by this paper
• Exploring the O-GlcNAc proteome: direct identification of O-GlcNAc-modified proteins from the brain.

  2004cited by this paper
• Nucleocytoplasmic glycosylation, O-GlcNAc: identification and site mapping.

  2004cited by this paper
• Ogt-Dependent X-Chromosome-Linked Protein Glycosylation Is a Requisite Modification in Somatic Cell Function and Embryo Viability

  2004cited by this paper
• The glamour and gloom of glycogen synthase kinase-3.

  2004cited by this paper
• Causes and consequences of disturbances of cerebral glucose metabolism in sporadic Alzheimer disease: therapeutic implications.

  2004cited by this paper
• The potential role of tau protein O-glycosylation in Alzheimer's disease

  2004cited by this paper
• Tau Becomes a More Favorable Substrate for GSK-3 When It Is Prephosphorylated by PKA in Rat Brain*

  2004cited by this paper
• Evidence of a balance between phosphorylation and O-GlcNAc glycosylation of Tau proteins--a role in nuclear localization.

  2003cited by this paper
• Dephosphorylation of microtubule‐associated protein tau by protein phosphatase 5

  2003cited by this paper
• Does Diabetes Protect or Provoke Alzheimer's Disease? Insights Into the Pathobiology and Future Treatment of Alzheimer's Disease

  2003cited by this paper
• Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies.

  2002cited by this paper
• Role of glycosylation in hyperphosphorylation of tau in Alzheimer's disease

  2002cited by this paper
• Characterization of a mouse monoclonal antibody specific for O-linked N-acetylglucosamine.

  2001cited by this paper
• Inhibition of Protein Phosphatase 2A Overrides Tau Protein Kinase I/Glycogen Synthase Kinase 3β and Cyclin-dependent Kinase 5 Inhibition and Results in Tau Hyperphosphorylation in the Hippocampus of Starved Mouse*

  2001cited by this paper
• Declining brain activity in cognitively normal apolipoprotein E ɛ4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease

  2001cited by this paper
• Wheat germ agglutinin‐binding glycoproteins are decreased in Alzheimer's disease cerebrospinal fluid

  2001cited by this paper
• O-Glycosylation of Nuclear and Cytosolic Proteins

  2000cited by this paper
• Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease.

  2000cited by this paper
• Dynamic Regulation of Expression and Phosphorylation of Tau by Fibroblast Growth Factor-2 In Neural Progenitor Cells from Adult Rat Hippocampus

  1999cited by this paper
• Reduction of O-Linked N-Acetylglucosamine-Modified Assembly Protein-3 in Alzheimer’s Disease

  1998cited by this paper
• Dynamic O-linked glycosylation of nuclear and cytoskeletal proteins.

  1997cited by this paper
• Monoclonal antibody PHF‐1 recognizes tau protein phosphorylated at serine residues 396 and 404

  1994cited by this paper
• Dephosphorylation of microtubule‐associated protein tau by protein phosphatase‐1 and ‐2C and its implication in Alzheimer disease

  1994cited by this paper
• Application of synthetic phospho‐ and unphospho‐ peptides to identify phosphorylation sites in a subregion of the tau molecule, which is modified in Alzheimer's disease

  1993cited by this paper
• Characterization of Two Distinct Monoclonal Antibodies to Paired Helical Filaments: Further Evidence for Fetal‐Type Phosphorylation of the τ in Paired Helical Filaments

  1993cited by this paper
• Intermediary metabolism disturbance in AD/SDAT and its relation to molecular events.

  1993cited by this paper
• Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer's disease. Pathophysiologic implications.

  1992cited by this paper
• Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease.

  1989cited by this paper
• Abnormal phosphorylation of the microtubule-associated protein? (tau) in Alzheimer cytoskeletal pathology

  1987cited by this paper
• Monoclonal antibodies identify a group of nuclear pore complex glycoproteins

  1987cited by this paper
• Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology.

  1986cited by this paper
• Computed Tomography and Positron Emission Transaxial Tomography Evaluations of Normal Aging and Alzheimer's Disease

  1983cited by this paper

• Decoding Glycosylation in Neurodegenerative Diseases: Mechanistic Insights and Therapeutic Opportunities

  2025cites this paper
• Sex alters thyroid hormone’s effect on protein O-GlcNAcylation in the aged mouse heart

  2025cites this paper
• Cross-Talk Between Tau O-GlcNAcylation and the Formation of the Early Driver of Neurodegeneration (Cis P-Thr231-Pro Tau) in Primary Cortical Neurons

  2025cites this paper
• Glycosylation in neuroinflammation: mechanisms, implications, and therapeutic strategies for neurodegenerative diseases

  2025cites this paper
• The alteration and role of glycoconjugates in Alzheimer’s disease

  2024cites this paper
• Opportunities for Therapeutic Modulation of O-GlcNAc

  2024cites this paper
• The O-GlcNAc Modification of Recombinant Tau Protein and Characterization of the O-GlcNAc Pattern for Functional Study.

  2024cites this paper
• Updates in Alzheimer's disease: from basic research to diagnosis and therapies

  2024cites this paper
• Advances in protein glycosylation and its role in tissue repair and regeneration

  2023cites this paper
• Brain O-GlcNAcylation: From Molecular Mechanisms to Clinical Phenotype.

  2023cites this paper
• O-GlcNAc transferase in astrocytes modulates depression-related stress susceptibility through glutamatergic synaptic transmission

  2023cites this paper
• Brain metabolism in Alzheimer’s disease: biological mechanisms of exercise

  2023cites this paper
• Diabetic Encephalopathy: Role of Oxidative and Nitrosative Factors in Type 2 Diabetes

  2022cites this paper
• Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers

  2022cites this paper
• In-depth Site-specific Analysis of N-glycoproteome in Human Cerebrospinal Fluid and Glycosylation Landscape Changes in Alzheimer's Disease

  2021cites this paper
• Tau Post-translational Modifications: Dynamic Transformers of Tau Function, Degradation, and Aggregation

  2021cites this paper
• O-GlcNAc cycling mediates energy balance by regulating caloric memory.

  2021cites this paper
• Mechanistic roles for altered O-GlcNAcylation in neurodegenerative disorders.

  2021cites this paper
• Proteomic Profiling of Astrocytic O-GlcNAc Transferase-Related Proteins in the Medial Prefrontal Cortex

  2021cites this paper
• Human brain organoids in Alzheimer’s disease

  2021cites this paper
• Thiamme2-G, a Novel O-GlcNAcase Inhibitor, Reduces Tau Hyperphosphorylation and Rescues Cognitive Impairment in Mice

  2021cites this paper
• Sleep Deprivation Affects Tau Phosphorylation in Human Cerebrospinal Fluid

  2020cites this paper
• Experimental Evidence of the Benefits of Acupuncture for Alzheimer's Disease: An Updated Review

  2020cites this paper
• Therapeutic Targeting Strategies for Early- to Late-Staged Alzheimer’s Disease

  2020cites this paper
• The Glucose Metabolic Pathway as A Potential Target for Therapeutics: Crucial Role of Glycosylation in Alzheimer’s Disease

  2020cites this paper
• It's complicated: The relationship between sleep and Alzheimer's disease in humans.

  2020cites this paper
• Prediction of human tau 3D structure, and interplay between O-β-GlcNAc and phosphorylation modifications in Alzheimer's disease: C. elegans as a suitable model to study these interactions in vivo.

  2020cites this paper
• The Involvement of Canonical Wnt Signaling in Memory Impairment Induced by Chronic Cerebral Hypoperfusion in Mice

  2020cites this paper
• O-GlcNAcylation as a Therapeutic Target for Alzheimer’s Disease

  2020cites this paper
• O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.

  2019cites this paper
• Neuroprotective Approach of Anti-Cancer Microtubule Stabilizers Against Tauopathy Associated Dementia: Current Status of Clinical and Preclinical Findings

  2019cites this paper
• Prospective of managing impaired brain insulin signalling in late onset Alzheimers disease with excisting diabetic drugs

  2019cites this paper
• Molecular Connection Between Diabetes and Dementia.

  2019cites this paper
• Cerebral small vessel disease and the risk of Alzheimer's disease: A systematic review.

  2018cites this paper
• Therapeutic potential of rescuing protein O-GlcNAcylation in tau-related pathologies

  2018cites this paper
• Too sweet to resist: Control of immune cell function by O-GlcNAcylation.

  2018cites this paper
• O-GlcNAcylation and neuronal energy status: Implications for Alzheimer's disease.

  2018cites this paper
• Investigating the neuroprotective role of OGA inhibition by Thiamet-G against Alzheimer\'s disease

  2018cites this paper
• Role of phosphatidylcholine-DHA in preventing APOE4-associated Alzheimer’s disease

  2018cites this paper
• O-GlcNAc cycling in the developing, adult and geriatric brain

  2018cites this paper
• Bilateral Implantation of Shear Stress Modifier in ApoE Knockout Mouse Induces Cognitive Impairment and Tau Abnormalities

  2018cites this paper
• Nutrient regulation of signaling and transcription

  2018cites this paper
• Proteomic identification of altered protein O-GlcNAcylation in a triple transgenic mouse model of Alzheimer's disease.

  2018cites this paper
• Nature of Tau-Associated Neurodegeneration and the Molecular Mechanisms

  2018cites this paper
• GFAT1 phosphorylation by AMPK promotes VEGF-induced angiogenesis.

  2017cites this paper
• Early and Persistent O-GlcNAc Protein Modification in the Streptozotocin Model of Alzheimer’s Disease

  2017cites this paper
• Functional significance of O‐GlcNAc modification in regulating neuronal properties

  2017cites this paper
• The emerging link between O-GlcNAcylation and neurological disorders

  2017cites this paper
• Tau protein in neurodegenerative diseases - a review.

  2017cites this paper
• Tau Protein

  2017cites this paper
• Glucose Transporters at the Blood-Brain Barrier: Function, Regulation and Gateways for Drug Delivery

  2017cites this paper
• Characterization of Structures and Dynamics of Intrinsically Disordered Domain and Proteins Using Time Resolved-Hydrogen Deuterium Exchange Mass Spectrometry

  2017cites this paper
• Glial contributions to neurodegeneration in tauopathies

  2017cites this paper
• Production of O-GlcNAc Modified Recombinant Tau in E. coli and Detection of Ser400 O-GlcNAc Tau In Vivo.

  2017cites this paper
• Tau and tauopathies.

  2016cites this paper
• O‐GlcNAcylation: A regulator of tau pathology and neurodegeneration

  2016cites this paper
• Roles of O-GlcNAc in chronic diseases of aging.

  2016cites this paper
• Roles of O-GlcNAcylation on amyloid-β precursor protein processing, tau phosphorylation, and hippocampal synapses dysfunction in Alzheimer’s disease

  2016cites this paper
• The nutrient sensor OGT in PVN neurons regulates feeding

  2016cites this paper
• Intracellular and extracellular O-linked N-acetylglucosamine in the nervous system.

  2015cites this paper
• Microtubule-associated protein tau as a therapeutic target in Alzheimer's disease

  2014cites this paper
• Tau hyperphosphorylation induces apoptotic escape and triggers neurodegeneration in Alzheimer’s disease

  2014cites this paper
• Chronic cerebral hypoperfusion causes decrease of O-GlcNAcylation, hyperphosphorylation of tau and behavioral deficits in mice

  2014cites this paper
• From Chronic Cerebral Hypoperfusion to Alzheimer-Like Brain Pathology and Neurodegeneration

  2014cites this paper
• Deregulation of brain insulin signaling in Alzheimer’s disease

  2014cites this paper
• The role of protein glycosylation in Alzheimer disease

  2014cites this paper
• The Emerging Link between O-GlcNAc and Alzheimer Disease*

  2014cites this paper
• O-GlcNAcylation of Neuronal Proteins: Roles in Neuronal Functions and in Neurodegeneration.

  2014cites this paper
• Alzheimer disease therapeutics: focus on the disease and not just plaques and tangles.

  2014cites this paper
• Effects of Treadmill Exercise on Brain Insulin Signaling, Glucose Metabolism and Tau Hyperphosphorylation in Intracerebroventricular Streptozotocin Induced-Memory Impairment in Rats

  2014cites this paper
• O-GlcNAc and neurodegeneration: biochemical mechanisms and potential roles in Alzheimer's disease and beyond.

  2014cites this paper
• Okadaic acid induced neurotoxicity: an emerging tool to study Alzheimer's disease pathology.

  2013cites this paper
• Insulin Resistance: A Bridge between T2DM and Alzheimer's Disease

  2013influential citation
• Development of functional tools to study the role of O-GlcNAc in tau biology

  2013cites this paper
• Hyperphosphorylation-Induced Tau Oligomers

  2013cites this paper
• Preclinical evaluation of the novel monoclonal antibody H6-11 for prostate cancer imaging.

  2013cites this paper
• Synapsin-1 and tau reciprocal O-GlcNAcylation and phosphorylation sites in mouse brain synaptosomes

  2013cites this paper
• Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation.

  2012cites this paper
• Molecular Mechanisms Underlie Alzheimer-like Tau Hyperphosphorylation and Neurodegeneration*: Molecular Mechanisms Underlie Alzheimer-like Tau Hyperphosphorylation and Neurodegeneration*

  2012cites this paper
• O-GlcNAc cycling modulates neurodegeneration

  2012cites this paper
• Metabolic Reserve as a Determinant of Cognitive Aging

  2012cites this paper
• Abnormal Hyperphosphorylation of Tau: Sites, Regulation, and Molecular Mechanism of Neurofibrillary Degeneration

  2012cites this paper
• Biochemistry and cell biology of tau protein in neurofibrillary degeneration.

  2012cites this paper
• Developmental Regulation of Protein O-GlcNAcylation, O-GlcNAc Transferase, and O-GlcNAcase in Mammalian Brain

  2012cites this paper
• Differential Effects of an O-GlcNAcase Inhibitor on Tau Phosphorylation

  2012cites this paper
• Strategies for Inhibiting Protein Aggregation: Therapeutic Approaches to Protein-Aggregation Diseases

  2012cites this paper
• The Role of Glucose Transporters in Brain Disease: Diabetes and Alzheimer’s Disease

  2012cites this paper
• Chapter 2 : The Roles of O-GlcNAc Glycosylation in the Brain

  2011cites this paper
• Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes

  2011cites this paper
• Cerebrovascular disorders: molecular insights and therapeutic opportunities

  2011cites this paper
• Human Alzheimer's disease synaptic O-GlcNAc site mapping and iTRAQ expression proteomics with ion trap mass

  2011cites this paper
• Human Alzheimer’s disease synaptic O-GlcNAc site mapping and iTRAQ expression proteomics with ion trap mass spectrometry

  2011cites this paper
• Targeting Post-translational Modifications on Tau as a Therapeutic Strategy for Alzheimer's Disease

  2011cites this paper
• Lectin‐affinity chromatography brain glycoproteomics and Alzheimer disease: Insights into protein alterations consistent with the pathology and progression of this dementing disorder

  2011cites this paper
• Tau phosphorylation and aggregation as a therapeutic target in tauopathies.

  2010cites this paper
• Targeting Tau Protein in Alzheimer’s Disease

  2010cites this paper
• PP2A Regulates Tau Phosphorylation Directly and also Indirectly via Activating GSK-3β

  2010cites this paper
• Effects of estrogen in the brain: is it a neuroprotective agent in Alzheimer's disease?

  2010cites this paper
• Transcriptional regulation of mortalin and the hexosamine biosynthetic pathway by the orphan nuclear receptor ERRalpha

  2010cites this paper
• Hypoxia‐inducible factor 1: a new hope to counteract neurodegeneration?

  2010cites this paper